deltatrials
Recruiting OBSERVATIONAL NCT00825929

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. (PANNA)

Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections
Updated 21 times since 2017 Last updated: Jan 10, 2025 Started: Feb 28, 2009 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00825929, this observational or N/A phase trial focuses on HIV Infections and remains actively recruiting participants. Sponsored by Bristol-Myers Squibb, it has been updated 21 times since 2009, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshot~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Aug 2020 · 18 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – present · 18 months · monthly snapshot

Change History

21 versions recorded

  1. Feb 2025 — Present [monthly]

    Recruiting

  2. Sep 2024 — Feb 2025 [monthly]

    Recruiting

  3. Aug 2024 — Sep 2024 [monthly]

    Recruiting

  4. Jul 2024 — Aug 2024 [monthly]

    Recruiting

  5. Dec 2022 — Jul 2024 [monthly]

    Recruiting

▶ Show 16 earlier versions

  1. Sep 2022 — Dec 2022 [monthly]

    Recruiting

  2. Jun 2022 — Sep 2022 [monthly]

    Recruiting

  3. Mar 2022 — Jun 2022 [monthly]

    Recruiting

  4. Dec 2021 — Mar 2022 [monthly]

    Recruiting

  5. Sep 2021 — Dec 2021 [monthly]

    Recruiting

  6. Apr 2021 — Sep 2021 [monthly]

    Recruiting

  7. Jan 2021 — Apr 2021 [monthly]

    Recruiting

  8. Dec 2020 — Jan 2021 [monthly]

    Recruiting

  9. Nov 2020 — Dec 2020 [monthly]

    Recruiting

  10. Aug 2020 — Nov 2020 [monthly]

    Recruiting

  11. Feb 2019 — Aug 2020 [monthly]

    Recruiting

  12. Jun 2018 — Feb 2019 [monthly]

    Recruiting

  13. May 2018 — Jun 2018 [monthly]

    Recruiting

  14. Apr 2018 — May 2018 [monthly]

    Recruiting

    Phase: NA → None

  15. Aug 2017 — Apr 2018 [monthly]

    Recruiting NA

  16. Jan 2017 — Aug 2017 [monthly]

    Recruiting NA

    First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Janssen Pharmaceutica
  • Merck Sharp & Dohme LLC
  • PENTA Foundation
  • Radboud University Medical Center
  • ViiV Healthcare
Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Badalona, Spain , Berlin, Germany , Bonn, Germany , Brighton, United Kingdom , Brussels, Belgium , Cologne, Germany , Dublin, Ireland , Frankfurt am Main, Germany , Granada, Spain and 6 more locations